DDrare: Database of Drug Development for Rare Diseases

Searched query = "Congenital nephrogenic diabetes insipidus", "Hereditary nephrogenic diabetes insipidus", "Nephrogenic diabetes insipidus"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = ACETAZOLAMIDE; Acetate; Acetazolamide; Acetazolamide Sandoz 250; Adempas; Amiloride; Atorvastatin; CALCITONIN (SALMON); Calcitonin; Chlorothiazide; Confortid; DESMOPRESSIN ACETATE TRIHYDRATE; Desmopressin; Desmopressin acetate trihydrate; Desmopressine; Desmopressine nasal spray 10 mg/ml, flacon 60 doses; Esidrix; FLUCONAZOLE; Fluconazole; HYDROCHLOROTHIAZIDE; Hydrochloorthiazide; Hydrochlorothiazide; Hydrochlorothiazide/amiloride; INDOMETACIN; Indometacin; Indomethacin; Losec; Magnesium; Metformin; Miacalcic; Midamor; OMEPRAZOLE MAGNESIUM; Omeprazole; RIOCIGUAT; Riociguat; SILDENAFIL; SILDENAFIL CITRATE; SPIRONOLACTONE; SUB21605; Salmon; Sildenafil; Spirix; Spironolactone; Tolvaptan; Viagra

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-jRCTs031180369	12/04/2018	18/03/2019	Tolvaptan for nephrogenic diabetes insipidus	Exploratory study of tolvaptan use for nephrogenic diabetes insipidus caused by mutation in vasopressin type 2 receptor - Tolvaptan use for NDI by V2R mutation	Nephrogenic diabetes insipidus Nephrogenic diabetes insipidus, polyuria;D018500	Starting tolvaptan from 60 mg and dose up to 90mg and 120mg in every 1 or 2 days.	Makita Noriko	NULL	Recruiting	>= 20age old	Not applicable	Both	3		Japan
2	JPRN-UMIN000021708	2016/04/18	18/04/2016	A study to evaluate effect and safety of Tolvaptan in Nephrogenic Diabetes Insipidus caused by mutations in the vasopressin type 2 receptor gene.	A study to evaluate effect and safety of Tolvaptan in Nephrogenic Diabetes Insipidus caused by mutations in the vasopressin type 2 receptor gene. - A study to evaluate effect and safety of Tolvaptan in Nephrogenic Diabetes Insipidus caused by mutations in the vasopressin type 2 receptor gene.	Nephrogenic Diabetes Insipidus caused by mutations in the vasopressin type 2 receptor gene	Administration of Tolvaptan once per day (60mg/day, 90mg/day, 120mg/day), each dose for two days.	Department of Nephrology and Endocrinology, The University of Tokyo Hospital	NULL	Recruiting	20years-old	Not applicable	Male and Female	3	Not selected	Japan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

JPRN-jRCTs031180369

12/04/2018

18/03/2019

Tolvaptan for nephrogenic diabetes insipidus

Exploratory study of tolvaptan use for nephrogenic diabetes insipidus caused by mutation in vasopressin type 2 receptor - Tolvaptan use for NDI by V2R mutation

Nephrogenic diabetes insipidus
Nephrogenic diabetes insipidus, polyuria;D018500

Starting tolvaptan from 60 mg and dose up to 90mg and 120mg in every 1 or 2 days.

Makita Noriko

NULL

Recruiting

>= 20age old

Not applicable

Both

Japan

JPRN-UMIN000021708

2016/04/18

18/04/2016

A study to evaluate effect and safety of Tolvaptan in Nephrogenic Diabetes Insipidus caused by mutations in the vasopressin type 2 receptor gene.

A study to evaluate effect and safety of Tolvaptan in Nephrogenic Diabetes Insipidus caused by mutations in the vasopressin type 2 receptor gene. - A study to evaluate effect and safety of Tolvaptan in Nephrogenic Diabetes Insipidus caused by mutations in the vasopressin type 2 receptor gene.

Nephrogenic Diabetes Insipidus caused by mutations in the vasopressin type 2 receptor gene

Administration of Tolvaptan once per day (60mg/day, 90mg/day, 120mg/day), each dose for two days.

Department of Nephrology and Endocrinology, The University of Tokyo Hospital

NULL

Recruiting

20years-old

Not applicable

Male and Female

Not selected

Japan